Fusidic acid for Behçet's colitis: a novel approach to T-cell specific immunosuppressive therapy.
A 33-year-old patient suffered from recurring Beh,cet's colitis despite treatment with corticosteroids and later cyclosporin. The patient was then successfully shifted from cyclosporin, a T-cell specific immunosuppressant, to fusidic acid treatment (500 mg t.i.d.). During fusidic acid treatment, he went into complete remission, and his prednisolone dose could be reduced from 30 to 5 mg/day. The case report substantiates recent in vitro data indicating that fusidic acid has a similar effect on T-cell function as cyclosporin. It is suggested that the effect of fusidic acid in other chronic immunoinflammatory diseases should be examined.
Langholz
E
E
Medicinsk gastroenterologisk afdeling C, Københavns.
Brynskov
J
J
Freund
L G
LG
Bendtzen
K
K
D000328:Adult; D001528:Behcet Syndrome / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D003092:Colitis / Q000150:complications / Q000188:drug therapy / Q000276:immunology; D005672:Fusidic Acid / Q000627:therapeutic use*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008297:Male; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology
D007166:Immunosuppressive Agents; D005672:Fusidic Acid